Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Lymphoma, Non-Hodgkin 3Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Infectious Mononucleosis 1

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Whole-Body Irradiation 4itacitinib 3angiotensin I (1-7) 3pembrolizumab 2Tacrolimus 2Olanzapine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2INCB039110 2CTLA-4 Antigen 2Busulfan 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2AP 1903 reagent 2tazemetostat 1tafasitamab 1ruxolitinib 1pomalidomide 1ofatumumab 1merphos 1lopinavir-ritonavir drug combination 1ivosidenib 1ibrutinib 1fedratinib 1enasidenib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Neoplasms × Bendamustine Hydrochloride × Clear all
NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Yale University

Phase 2 Withdrawn
Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Nevada Cancer Institute

Phase 2 Withdrawn
37 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡